Skip to content
Sign in
Artwork for The Chain: Protein Engineering Podcast
The Chain: Protein Engineering Podcast · August 11 · 39 min

Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. Links from this episode: Genentech mAbs

0:00 · Welcome To The Chain-39:03
Play in
Transcript file

transcript

No transcript — this publisher did not publish one.

show notes

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. 

Links from this episode:  
Genentech
mAbs 

links2

chapters

12 chapters

more episodes

All episodes